# APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT05186012** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 51 (estimated)

## Conditions studied

- NHL, Adult

## Interventions

- **DRUG:** APG-1252
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT05186012
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-14
- **Primary completion:** 2025-09
- **Final completion:** 2026-03
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186012, "APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05186012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*